Chitosan/Polycyclodextrin (CHT/PCD)-Based Sponges Delivering VEGF to Enhance Angiogenesis for Bone Regeneration
In: Pharmaceutics Pharmaceutics, 2020, 12 (9), pp.784. ⟨10.3390/pharmaceutics12090784⟩, Jg. 12 (2020), Heft 784, p 784
Online
unknown
Zugriff:
Vascularization is one of the main challenges in bone tissue engineering (BTE). In this study, vascular endothelial growth factor (VEGF), known for its angiogenic effect, was delivered by our developed sponge, derived from a polyelectrolyte complexes hydrogel between chitosan (CHT) and anionic cyclodextrin polymer (PCD). This sponge, as a scaffold for growth factor delivery, was formed by freeze-drying a homogeneous CHT/PCD hydrogel, and thereafter stabilized by a thermal treatment. Microstructure, water-uptake, biodegradation, mechanical properties, and cytocompatibility of sponges were assessed. VEGF-delivery following incubation in medium was then evaluated by monitoring the VEGF-release profile and its bioactivity. CHT/PCD sponge showed a porous (open porosity of 87.5%) interconnected microstructure with pores of different sizes (an average pore size of 153 &mu
m), a slow biodegradation (12% till 21 days), a high water-uptake capacity (~600% in 2 h), an elastic property under compression (elastic modulus of compression 256 ±
4 kPa), and a good cytocompatibility in contact with osteoblast and endothelial cells. The kinetic release of VEGF was found to exert a pro-proliferation and a pro-migration effect on endothelial cells, which are two important processes during scaffold vascularization. Hence, CHT/PCD sponges were promising vehicles for the delivery of growth factors in BTE.
| Titel: |
Chitosan/Polycyclodextrin (CHT/PCD)-Based Sponges Delivering VEGF to Enhance Angiogenesis for Bone Regeneration
|
|---|---|
| Autor/in / Beteiligte Person: | Palomino-Durand, Carla ; Chai, Feng ; Martel, Bernard ; Blanchemain, Nicolas ; Lopez, Marco ; Marchandise, Pierre ; Université de Lille, LillOA ; Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 (MBLC - ADDS) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille) ; Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 (MABLab (ex-pmoi)) ; Université du Littoral Côte d'Opale (ULCO)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille) ; Unité Matériaux et Transformations - UMR 8207 (UMET) ; Centrale Lille-Institut de Chimie du CNRS (INC)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE) ; Lille, CHU ; CNRS ; ENSCL ; INRA ; Inserm ; Université de Lille ; Unité Matériaux et Transformations (UMET) - UMR 8207 ; Médicaments et Biomatériaux à libération contrôlée : Mécanismes et Optimisation - U1008 [MBLC] ; Advanced Drug Delivery Systems (ADDS) - U1008 ; Physiopathologie des Maladies Osseuses Inflammatoires (PMOI) - ULR 4490 ; Unité de Taphonomie Médico-Légale (UTML) - ULR 7367 ; Unité Matériaux et Transformations - UMR 8207 [UMET] ; Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS] |
| Link: | |
| Zeitschrift: | Pharmaceutics Pharmaceutics, 2020, 12 (9), pp.784. ⟨10.3390/pharmaceutics12090784⟩, Jg. 12 (2020), Heft 784, p 784 |
| Veröffentlichung: | HAL CCSD, 2020 |
| Medientyp: | unknown |
| ISSN: | 1999-4923 (print) |
| Schlagwort: |
|
| Sonstiges: |
|